Loading...
  • viral
  • When antibodies try to mimic the receptor, they touch a lot of other parts of the viral envelope that HIV can change with ease," said TSRI Research Associate Matthew Gardner, the first author of the study with Lisa M. Kattenhorn of Harvard Medical School. (scripps.edu)
  • HIV-1 protease is an enzyme required for the proteolytic cleavage of the viral polyprotein precursors into the individual functional proteins found in infectious HIV-1. (pharmacycode.com)
  • We are working towards the development of novel carbohydrate-based agents that are capable of binding the gp120 protein on the viral surface, such that viral entry into an uninfected host cell is prevented. (openrepository.com)
  • SUSTIVA (efavirenz) works by lowering the amount of HIV-1 in the blood (viral load). (pharmacycode.com)
  • When taken with other anti-HIV medicines, SUSTIVA has been shown to reduce viral load and increase the number of CD4+ cells, a type of immune cell in blood. (pharmacycode.com)
  • Factors associated with viral rebound in HIV-1-infected individuals enrolled in a therapeutic HIV-1 gag vaccine trial. (actgnetwork.org)
  • Accurate and reliable measures of ART adherence will be needed in the transition from reactive response to proactive prevention of viral rebound in the era of chronic human immunodeficiency virus (HIV) disease management. (nih.gov)
  • therapeutic
  • It relates oral presentations given by Romas Geleziunas, on behalf of Gilead, and Roger Sutmuller, on behalf of Janssen on the search for new therapeutic strategies targeting latent HIV reservoirs. (hiv-reservoir.net)
  • binds
  • With this knowledge, Farzan and his team developed the new drug candidate so that it binds to two sites on the surface of the virus simultaneously, preventing entry of HIV into the host cell. (scripps.edu)
  • Data from the new study showed the drug candidate binds to the envelope of HIV-1 more potently than the best broadly neutralizing antibodies against the virus. (scripps.edu)
  • genetic
  • HIV fuses with the cell and inserts its own genetic material-in this case, single-stranded RNA-and transforms the host cell into a HIV manufacturing site. (scripps.edu)
  • Genetic analysis implicates resistin in HIV lipodystrophy. (actgnetwork.org)
  • human
  • HIV-2 RT and eukaryotic DNA polymerases (such as human DNA polymerases alpha, beta, or sigma) are not inhibited by nevirapine. (pharmacycode.com)
  • effective
  • A second, closely related compound, JLJ506, is also highly effective against wild-type HIV, as well as against two common mutant forms of the virus. (yale.edu)
  • drugs
  • Two such agents discovered at Yale could result in HIV drugs that are 10 to 2000 times more potent than those now on the market. (yale.edu)
  • acquire
  • The majority of MSM acquire HIV after exposure to the rectal mucosa through unprotected receptive anal intercourse. (clinicaltrials.gov)
  • structural
  • Especially, terpenes and phenol substances have gained much interest due to their significant anti-HIV activities along with their structural diversity. (ingentaconnect.com)
  • scientists
  • The discoveries mark another major achievement by Yale scientists in fighting HIV. (yale.edu)
  • The 2 talks given in a row during this Thursday December 7 afternoon, in front of an audience of more than 210 HIV scientists, contained the same message: some of the major pharmaceutical companies are addressing the search of an HIV cure very seriously. (hiv-reservoir.net)
  • cells
  • Once injected into muscle tissue, like HIV itself, the vehicle turns those cells into "factories" that could produce enough of the new protective protein to last for years, perhaps decades, Farzan said. (scripps.edu)
  • This is the culmination of more than a decade's worth of work on the biochemistry of how HIV enters cells," Farzan said. (scripps.edu)
  • It remains to be determined if this kind of agent is able to enhance immunity to help eliminate HIV-infected cells (figure 5). (hiv-reservoir.net)
  • Evaluation
  • Evaluation of high-protein supplementation in weight-stable HIV-positive subjects with a history of weight loss: a randomized, double-blind, multicenter trial. (actgnetwork.org)
  • targets
  • When HIV infects a cell, it targets the CD4 lymphocyte, an integral part of the body's immune system. (scripps.edu)
  • virus
  • The study shows that the new drug candidate blocks every strain of HIV-1, HIV-2 and SIV (simian immunodeficiency virus) that has been isolated from humans or rhesus macaques, including the hardest-to-stop variants. (scripps.edu)